We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




STI Molecular Test Delivers Rapid POC Results for Treatment Guidance

By LabMedica International staff writers
Posted on 24 Dec 2025

An affordable, rapid molecular diagnostic for sexually transmitted infections (STIs) has the potential to be globally relevant, particularly in resource-limited settings where rapid, point-of-care results can significantly impact both individual treatment and antibiotic stewardship. More...

Scout Health (Santa Clara, CA, USA) is finalizing the development of STI Scout, a rapid molecular test for detecting Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct) infections in under 30 minutes. The STI Scout test can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility. Designed for both point-of-care (POC) and over-the-counter (OTC) use, the test runs on the Scout Hub near-patient molecular platform, which enables earlier organism identification, resistance prediction, and better antimicrobial stewardship.

The Scout Hub test platform leverages a proprietary molecular chemistry that enables rapid detection of multiple pathogens in a single tube. This results in a test platform with orders-of-magnitude lower cost than commercially available clinical solutions while maintaining a sensitivity that can detect targets missed by rapid antigen tests. Because the system relies on minimal hardware and low-cost consumables, it can be manufactured and scaled efficiently. STI Scout uses the Scout Connect mobile app, which provides instructions, tracks results, and eventually will also allow patients to connect digitally to a healthcare provider.

Scout has been awarded additional funding from CARB-X to investigate a pilot in a low- or middle-income country, reflecting the platform's ability to extend high-quality molecular STI testing to resource and infrastructure-constrained settings. Expanding access to accurate molecular testing in settings where treatment is often empirical can support more appropriate therapy decisions and help reduce unnecessary antibiotic use.

"Cost is the number one barrier for adoption of rapid molecular testing in the US and abroad,” said Alex Jiao, PhD, CEO and Co-Founder of Scout. “COVID showed the limits of expensive, complex systems. Even with strong performance, their economics made sustained adoption impossible. Scout has focused on lowering cost through advances in chemistry and simplifying test design, enabling a platform that meets molecular performance requirements at a price point that supports a lasting, impactful solution."

Related Links:
Scout Health 


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Homocysteine Quality Control
Liquichek Homocysteine Control
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.